DBV Technologies (DBVT) Cash from Operations (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Cash from Operations of 52600000.0 for Q2 2026, down 55.16% year-on-year from 117311842.11 in Q2 2025, and down 7.13% on a QoQ basis from 49100000.0 in Q1 2026.
DBV Technologies (DBVT) Cash from Operations (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Cash from Operations for 7 consecutive years, with 52600000.0 the latest figure, recorded in Q2 2026.
- Quarterly Cash from Operations fell 55.16% year-over-year to 52600000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 169281000.0 (down 91.69% YoY) and the FY2025 annual result came in at 121181000.0, down 15.99% from the prior year.
- Cash from Operations fell to 52600000.0 in Q2 2026 per DBVT's latest filing, from 49100000.0 in the prior quarter.
- Over the last five years, Cash from Operations for DBVT reached as high as 1483000.0 in Q1 2022 and fell as low as 52600000.0 in Q2 2026.
- A 5-year average of 25704111.11 and a median of 23171000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations soared 95.9% — and 2023, when it slumped 1305.33%.
- Year by year, Cash from Operations stood at 23885000.0 in 2022, then surged by 42.7% to 13686000.0 in 2023, then gained by 10.48% to 12252000.0 in 2024, then tumbled by 187.08% to 35173000.0 in 2025, then sank by 49.55% to 52600000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 52600000.0, 49100000.0, and 35173000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -52.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.60 Mn |
| Jun 30, 2026 | -52.60 Mn |
| Mar 31, 2026 | -49.10 Mn |
| Mar 31, 2026 | -49.10 Mn |
| Dec 31, 2025 | -35.17 Mn |
| Dec 31, 2025 | -35.17 Mn |
| Sep 30, 2025 | -32.41 Mn |
| Sep 30, 2025 | -32.41 Mn |
| Jun 30, 2025 | -33.90 Mn |
| Jun 30, 2025 | -33.90 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Dec 31, 2024 | -12.25 Mn |
| Dec 31, 2024 | -12.25 Mn |
| Sep 30, 2024 | -22.46 Mn |
| Sep 30, 2024 | -22.46 Mn |
| Jun 30, 2024 | -35.07 Mn |
| Jun 30, 2024 | -35.07 Mn |
| Mar 31, 2024 | -34.69 Mn |
| Mar 31, 2024 | -34.69 Mn |